Article information
Full text is only aviable in PDF
References
[1.]
World Health Organization.
The Rational Use of Drugs.
Report of the Conference of Experts, WHO, (1985),
[2.]
Ley 29/2006, de 26 de julio, de garantías y uso racional de los medicamentos y productos sanitarios. BOE número 178, 27 de julio de 2006.
[3.]
Inforcoan. Sistema de Contabilidad Analítica de Hospitales y Distritos. Servicio Andaluz de Salud. Seville: Consejería de Salud, Junta de Andalucía; 2009.
[4.]
L. Clark, M. Lebwohl.
The effect of weight on the efficacy of biologic therapy in patients with psoriasis.
J Am Acad Dermatol, 58 (2008), pp. 443-446
[5.]
K. Papp, J. Crowley, J.P. Ortonne, J. Leu, M. Okun, S.R. Gupta, et al.
Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
Br J Dermatol, 164 (2011), pp. 434-441
[6.]
A. Arcese, N. Aste, Bettacchini, Camplone, F. Cantoresi, M. Caproni, et al.
Treating psoriasis with etanercept in Italian clinical practice. Prescribing practices and duration of remission following discontinuation.
Clin Drug Invest, 30 (2010), pp. 507-516
[7.]
A.J. Blasco, P. Lázaro, C. Ferrándiz, A. García-Díez, J. Liso.
Efficiency of biologic agents in the treatment of moderate to severe psoriasis.
Actas Dermosifiliogr, 100 (2009), pp. 792-803
[8.]
A. Lloyd, P. Reeves, P. Conway, A. Reynolds, G. Baxter.
Economic evaluation of etanercept in the management of chronic plaque psoriasis.
Br J Dermatol, 160 (2009), pp. 380-386
Copyright © 2011. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
